Logo image of BMGL

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

NASDAQ:BMGL - Nasdaq - VGG0864B1031 - Common Stock - Currency: USD

2.25  -0.72 (-24.24%)

After market: 2.32 +0.07 (+3.11%)

Fundamental Rating

3

BMGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of BMGL get a neutral evaluation. Nothing too spectacular is happening here. BMGL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

BMGL had positive earnings in the past year.
BMGL had a negative operating cash flow in the past year.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 1M 2M 3M 4M

1.2 Ratios

With an excellent Return On Assets value of 11.76%, BMGL belongs to the best of the industry, outperforming 95.15% of the companies in the same industry.
BMGL has a Return On Equity of 24.18%. This is amongst the best in the industry. BMGL outperforms 91.26% of its industry peers.
With an excellent Return On Invested Capital value of 36.92%, BMGL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BMGL is significantly above the industry average of 9.71%.
The last Return On Invested Capital (36.92%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 11.76%
ROE 24.18%
ROIC 36.92%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40 50

1.3 Margins

BMGL's Profit Margin of 11.64% is amongst the best of the industry. BMGL outperforms 97.09% of its industry peers.
Looking at the Operating Margin, with a value of 32.46%, BMGL belongs to the top of the industry, outperforming 98.06% of the companies in the same industry.
Industry RankSector Rank
OM 32.46%
PM (TTM) 11.64%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BMGL is creating value.
Compared to 1 year ago, BMGL has about the same amount of shares outstanding.
BMGL has a better debt/assets ratio than last year.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

BMGL has an Altman-Z score of 6.61. This indicates that BMGL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BMGL (6.61) is better than 88.35% of its industry peers.
BMGL has a Debt/Equity ratio of 0.55. This is a neutral value indicating BMGL is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.55, BMGL is in line with its industry, outperforming 57.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z 6.61
ROIC/WACC4.45
WACC8.3%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2M 4M 6M

2.3 Liquidity

BMGL has a Current Ratio of 1.88. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
BMGL has a better Current ratio (1.88) than 69.90% of its industry peers.
BMGL has a Quick Ratio of 1.87. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
BMGL has a better Quick ratio (1.87) than 71.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.87
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BMGL have decreased strongly by -43.56% in the last year.
The Revenue has been growing slightly by 1.99% in the past year.
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

BMGL is valuated quite expensively with a Price/Earnings ratio of 32.14.
Compared to the rest of the industry, the Price/Earnings ratio of BMGL is on the same level as its industry peers.
When comparing the Price/Earnings ratio of BMGL to the average of the S&P500 Index (27.30), we can say BMGL is valued inline with the index average.
Industry RankSector Rank
PE 32.14
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BMGL is valued a bit cheaper than 66.02% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.44
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

BMGL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (7/11/2025, 8:00:02 PM)

After market: 2.32 +0.07 (+3.11%)

2.25

-0.72 (-24.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.65%
Ins Owner ChangeN/A
Market Cap42.28M
AnalystsN/A
Price TargetN/A
Short Float %7.22%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 32.14
Fwd PE N/A
P/S 3.59
P/FCF N/A
P/OCF N/A
P/B 7.45
P/tB 7.45
EV/EBITDA 10.44
EPS(TTM)0.07
EY3.11%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.63
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.76%
ROE 24.18%
ROCE 67.42%
ROIC 36.92%
ROICexc 1026.25%
ROICexgc 1026.25%
OM 32.46%
PM (TTM) 11.64%
GM N/A
FCFM N/A
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Debt/EBITDA 0.73
Cap/Depr 2.99%
Cap/Sales 0.12%
Interest Coverage 27.55
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.87
Altman-Z 6.61
F-Score3
WACC8.3%
ROIC/WACC4.45
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A